<p>Early treatment of patients with high-risk smoldering myeloma (HRSMM) has been shown to delay progression to multiple myeloma (MM), but not all patients respond well. Identifying biological predictors of response and resistance to treatment can help optimize treatment selection for patients and improve outcomes. Here, we investigate tumor and immune biomarkers of response to ixazomib, lenalidomide, and dexamethasone treatment (<a href="https://clinicaltrials.gov/study/NCT02916771">I-PRISM study</a>) that can be measured at diagnosis. We performed single-cell RNA sequencing (scRNAseq), coupled with B cell receptor and T cell receptor sequencing, on <a href="https://www.ncbi.nlm.nih.gov/gene/6382">CD138</a>+ tumor and <a href="https://www.ncbi.nlm.nih.gov/gene/6382">CD138</a>- immune cells, respectively, from the bone marrow of 20 patients enrolled in the I-PRISM study.</p>

Depth of Response Correlates with Improved Outcomes for Early    Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial    Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

Multiple Myeloma study with OTHER, RNA-Seq + 2 more data on dbGaP (20 participants)

phs003827 — Depth of Response Correlates with Improved Outcomes for Early    Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial    Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

Depth of Response Correlates with Improved Outcomes for Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone

Description

Applying For Access

Summary